Article info
PDFLetter
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
- Correspondence to Dr Caoilfhionn M Connolly, Rheumatology, Johns Hopkins University, Baltimore, Maryland 21224, USA; connolly{at}jhmi.edu
Citation
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases
Publication history
- Received February 23, 2021
- Revised March 6, 2021
- Accepted March 9, 2021
- First published March 19, 2021.
Online issue publication
July 13, 2021
Article Versions
- Previous version (19 March 2021).
- Previous version (25 March 2021).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage